tolvaptan has been researched along with Chronic Kidney Diseases in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 30 (69.77) | 24.3611 |
| 2020's | 13 (30.23) | 2.80 |
| Authors | Studies |
|---|---|
| Caprara, C; Corradi, V; Gastaldon, F; Giuliani, A; Marcello, M; Marturano, D; Rigato, M; Ronco, C; Zanella, M | 1 |
| Asahina, Y; Bessho, S; Iwatani, H; Kimura, Y; Koizumi, S; Mori, Y; Notsu, S; Shimomura, A; Yamato, M | 1 |
| Cobo, M; Delgado-Mallén, P; Escamilla, B; Estupiñán, S; Fernandez, JM; Ferrer-Moure, C; Gaspari, F; Gómez, MVP; González, IH; González-Delgado, A; González-Rinne, F; Luis-Lima, S; Marco, CO; Martín, LD; Mena, NN; Ortiz, A; Perera, CC; Porrini, E; Reyes, SP; Rodriguez Pérez, JC; Rodríguez, RM; Toledo, BG; Torres, A; Zulueta, BL | 1 |
| Fujiwara, A; Haze, T; Hirawa, N; Katsumata, M; Kawano, R; Kobayashi, Y; Komiya, S; Ohki, Y; Ozawa, M; Saka, S; Suzuki, S; Tamura, K | 1 |
| Amioka, M; Kinoshita, H; Matsumura, H; Morishima, N; Nakano, Y; Sairaku, A; Sanada, R | 1 |
| Quiroga, B; Torra, R | 1 |
| Cui, M; Wang, HY; Zhao, J; Zhu, ZY | 1 |
| Fujioka, H; Imamura, T; Kakeshita, K; Kinugawa, K; Koike, T; Yamazaki, H | 1 |
| Hasegawa, M; Hayashi, H; Inaguma, D; Koide, S; Ogata, S; Tagaya, T; Takahashi, K; Tsuboi, N; Yuzawa, Y | 1 |
| García-Arroyo, FE; Gonzaga, G; Iroz, A; Johnson, RJ; Muñoz-Jiménez, I; Osorio-Alonso, H; Reyes-García, JG; Roncal-Jiménez, CA; Sánchez-Lozada, LG; Tapia, E; Vecchio, M | 1 |
| Bovy, C; Delanaye, P; Jouret, F; Krzesinski, JM | 1 |
| Hirano, D; Ito, A; Kakegawa, D; Miwa, S; Takemasa, Y; Tokunaga, A; Umeda, C; Yuhei, K | 1 |
| Futamura, Y; Matsuyama, K; Okada, M; Sugiyama, K; Watanuki, H | 1 |
| Momomura, SI | 1 |
| Abdulhadi, B; Mezue, K; Rangaswami, J | 1 |
| Imai, R; Ishikawa, S; Koyasu, M; Murohara, T; Ozaki, Y; Shibata, R; Takemoto, K; Teraoka, T; Uchikawa, T; Uemura, Y; Watanabe, T; Watarai, M | 1 |
| Hamano, T; Isaka, Y; Iwatani, H; Kimura, Y; Minami, S; Mizui, M | 1 |
| Hamada, M; Ikeda, S; Kadota, H; Miyazaki, S; Ogimoto, A; Ohshima, K; Shimizu, H | 1 |
| Amano, T; Ando, H; Mizuno, T; Mukai, K; Murotani, K; Nakano, Y; Niwa, T; Takashima, H; Wakabayashi, H; Waseda, K; Watanabe, A | 1 |
| Chung, E; McGill, D; Sen, J | 1 |
| Nitta, K; Ogawa, T | 1 |
| Akashi, YJ; Inomata, T; Izumi, T; Kida, K; Sato, N; Shibagaki, Y; Tominaga, N | 1 |
| Isaka, Y; Iwatani, H; Kawabata, H; Nagai, N; Shirahase, K; Yamamichi, Y | 1 |
| Hiramatsu, E; Ito, C; Otsuka, Y; Shinjo, H; Takeda, A; Tanaka, A; Watanabe, Y | 1 |
| Akimoto, T; Imai, T; Maeshima, A; Masuda, T; Miki, A; Miyazawa, Y; Murakami, T; Muto, S; Myoga, A; Nagata, D; Nakagawa, S; Ohara, K; Okada, M; Saito, O; Sekiguchi, C; Sugase, T; Yoshizawa, H | 1 |
| Akimoto, T; Kobayashi, T; Maeshima, A; Masuda, T; Matsuoka, R; Murakami, T; Muto, S; Nagata, D; Nagayama, I; Nakagawa, S; Ohara, K; Saito, O | 1 |
| Imamura, T | 1 |
| Akimoto, T; Asakura, M; Fukaya, Y; Igarashi, Y; Maeshima, A; Masuda, T; Matsuoka, R; Miyazawa, Y; Murakami, T; Nagata, D; Nagayama, I; Nakagawa, S; Ohara, K; Oka, K; Saito, O | 1 |
| Hatano, M; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Komuro, I; Kyo, S; Maki, H; Minatsuki, S; Muraoka, H; Ono, M; Shiga, T; Yao, A | 1 |
| Bankir, L; Bouby, N; Ritz, E | 1 |
| Murasawa, T; Ohno, D; Otsuka, T; Sakai, Y; Sato, N; Tsuruoka, S | 1 |
| Bakker, SJ; Boertien, WE; Czerwiec, FS; de Jong, PE; Gansevoort, RT; Krasa, HB; Meijer, E; Oberdhan, D; Shoaf, SE; Struck, J | 1 |
| Bricmont, P; Mallikaarjun, S; Shoaf, SE | 1 |
| Boertien, WE; Czerwiec, FS; de Jong, PE; Engels, GE; Gansevoort, RT; Kappert, P; Krasa, HB; Meijer, E; Oberdhan, D; Ouyang, J; Renken, RJ; Struck, J; ter Horst, GJ; van der Jagt, EJ; van Oeveren, W | 1 |
| Hamano, T; Isaka, Y; Iwatani, H; Kawabata, H; Rakugi, H; Sakaguchi, Y; Yamamoto, R | 1 |
| Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N | 1 |
| Ito, Y; Kato, N; Kato, S; Katsuno, T; Kosugi, T; Maruyama, S; Matsuo, S; Mizuno, M; Ozaki, T; Sakata, F; Sato, W; Suzuki, Y; Tanaka, A; Tsuboi, N; Yasuda, Y | 1 |
| Imai, R; Ishikawa, S; Iwamiya, S; Kato, T; Koyasu, M; Mitsuda, T; Miura, A; Miura, T; Murohara, T; Ozaki, Y; Shibata, R; Takemoto, K; Uchikawa, T; Uemura, Y; Watarai, M | 1 |
| Horikawa, K; Nishi, H; Sawa, Y; Sekiya, N; Takahashi, T; Yamada, M | 1 |
| Banach, M; Bartnicki, P; Franczyk, B; Gluba-Brzózka, A; Rysz, J | 1 |
| Blais, JD; Chapman, AB; Czerwiec, FS; Devuyst, O; Gansevoort, RT; Ouyang, J; Perrone, RD; Sergeyeva, O; Torres, VE | 1 |
| Ehara, Y; Fujikawa, T; Fujita, M; Fujiwara, A; Hirawa, N; Kagimoto, M; Katsumata, M; Kobayashi, M; Kobayashi, Y; Okuyama, Y; Saka, S; Sumida, K; Tamura, K; Toya, Y; Umemura, S; Yamamoto, Y; Yasuda, G; Yatsu, K | 1 |
| Hatano, M; Imamura, T; Inaba, T; Kato, N; Kinugawa, K; Kyo, S; Maki, H; Minatsuki, S; Muraoka, H; Nagai, R; Shiga, T; Yao, A | 1 |
6 review(s) available for tolvaptan and Chronic Kidney Diseases
| Article | Year |
|---|---|
Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression.
Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Humans; Kidney; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan | 2022 |
[Therapeutic innovation in nephrology : 10 years of progress].
Topics: Disease Progression; Glomerular Filtration Rate; Humans; Kidney; Nephrology; Quality of Life; Renal Insufficiency, Chronic; Tolvaptan | 2020 |
Tolvaptan for Heart Failure in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Glomerular Filtration Rate; Heart Failure; Humans; Renal Insufficiency, Chronic; Tolvaptan | 2018 |
Clinical Impact of Left Ventricular Diastolic Dysfunction in Chronic Kidney Disease.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Antihypertensive Agents; Calcimimetic Agents; Calcium Channel Blockers; Diet, Sodium-Restricted; Diuretics; Echocardiography; Echocardiography, Doppler; Fibrosis; Heart Failure, Diastolic; Histamine Antagonists; Humans; Hypertrophy, Left Ventricular; Myocardium; Renal Dialysis; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Tolvaptan; Ventricular Dysfunction, Left | 2018 |
Vasopressin: a novel target for the prevention and retardation of kidney disease?
Topics: Animals; Benzazepines; Disease Progression; Humans; Hypertension, Renal; Incidence; Prevalence; Renal Insufficiency, Chronic; Tolvaptan; Vasopressins | 2013 |
Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Disease Progression; Drug Therapy, Combination; Humans; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan; TOR Serine-Threonine Kinases | 2016 |
7 trial(s) available for tolvaptan and Chronic Kidney Diseases
| Article | Year |
|---|---|
Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Renal Insufficiency, Chronic; Sodium; Tolvaptan; Water-Electrolyte Imbalance | 2022 |
Comparison of the effects of tolvaptan and furosemide on renal water and sodium excretion in patients with heart failure and advanced chronic kidney disease: a subanalysis of the K-STAR study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Diuretics; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Renal Elimination; Renal Insufficiency, Chronic; Sodium; Tolvaptan; Water | 2018 |
Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Female; Glomerular Filtration Rate; Hemodynamics; Hormone Antagonists; Humans; Kidney; Male; Middle Aged; Netherlands; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Renal Insufficiency, Chronic; Renal Plasma Flow, Effective; Time Factors; Tolvaptan; Treatment Outcome | 2013 |
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function.
Topics: Administration, Oral; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Tolvaptan | 2014 |
Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Pressure; Blood Urea Nitrogen; Creatinine; Diuretics; Drug Interactions; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Pilot Projects; Renal Insufficiency, Chronic; Tolvaptan; Uric Acid | 2015 |
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
Topics: Adolescent; Adult; Aged; Benzazepines; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Patient Safety; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Renal Insufficiency, Chronic; Research Design; Tolvaptan; Treatment Outcome; Young Adult | 2017 |
Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Blood Urea Nitrogen; Creatine; Diabetes Insipidus, Nephrogenic; Diuretics; Drug Monitoring; Female; Heart Failure; Humans; Hypovolemia; Logistic Models; Male; Middle Aged; Osmolar Concentration; Potassium; Predictive Value of Tests; Renal Insufficiency, Chronic; Sensitivity and Specificity; Sodium; Tolvaptan; Ultrasonography; Urine; Young Adult | 2013 |
30 other study(ies) available for tolvaptan and Chronic Kidney Diseases
| Article | Year |
|---|---|
[Slowing progression of chronic kidney disease in polycistic kidney disease patients with tolvaptan: from guidelines to clinical practice].
Topics: Antidiuretic Hormone Receptor Antagonists; Disease Progression; Humans; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan | 2021 |
Tolvaptan Reduces Extracellular Fluid per Amount of Body Fluid Reduction Less Markedly than Conventional Diuretics.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Body Fluids; Diuretics; Extracellular Fluid; Humans; Renal Insufficiency, Chronic; Tolvaptan; Water | 2022 |
Estimated GFR in autosomal dominant polycystic kidney disease: errors of an unpredictable method.
Topics: Adult; Creatinine; Glomerular Filtration Rate; Humans; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Tolvaptan | 2022 |
Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease.
Topics: Aged; Glomerular Filtration Rate; Heart Failure; Humans; Prospective Studies; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Tolvaptan | 2023 |
The efficacy of tolvaptan for heart failure in chronic kidney disease: A protocol for systematic review and meta-analysis.
Topics: Heart Failure; Humans; Meta-Analysis as Topic; Renal Insufficiency, Chronic; Research Design; Review Literature as Topic; Systematic Reviews as Topic; Tolvaptan | 2022 |
Impact of urine cyclic AMP relative to plasma arginine vasopressin on response to tolvaptan in patients with chronic kidney disease and heart failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Cyclic AMP; Heart Failure; Humans; Male; Prospective Studies; Renal Insufficiency, Chronic; Tolvaptan | 2023 |
Tolvaptan's Association with Low Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease and Acute Decompensated Heart Failure.
Topics: Acute Disease; Acute Kidney Injury; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Furosemide; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan | 2023 |
A Role for Both V1a and V2 Receptors in Renal Heat Stress Injury Amplified by Rehydration with Fructose.
Topics: Animals; Beverages; Fluid Therapy; Fructose; Heat-Shock Response; Hydrocortisone; Immediate-Early Proteins; Indoles; Kidney Cortex; Male; Oxidative Stress; Protein Serine-Threonine Kinases; Pyrrolidines; Rats; Rats, Wistar; Receptors, Vasopressin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Temperature; Tolvaptan; Up-Regulation | 2019 |
Impact of acute kidney injury in patients prescribed angiotensin-converting enzyme inhibitors over the first two years of life.
Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Child; Down Syndrome; Humans; Infant; Infant, Newborn; Male; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Tolvaptan | 2021 |
The Efficacy and Renal Protective Effect of Tolvaptan in Chronic Kidney Disease Patients after Open-Heart Surgery.
Topics: Cardiac Surgical Procedures; Humans; Protective Agents; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan; Treatment Outcome | 2021 |
Tolvaptan, Is It a Trump to Worsening Renal Function?
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Furosemide; Heart Failure; Humans; Renal Insufficiency, Chronic; Tolvaptan | 2017 |
Chronic Kidney Disease Contributing to Dyspnea in Patients With Heart Failure.
Topics: Dyspnea; Heart Failure; Humans; Renal Insufficiency, Chronic; Tolvaptan | 2017 |
Safety and Efficacy of Long-Term Use of Tolvaptan in Patients With Heart Failure and Chronic Kidney Disease.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Survival Rate; Time Factors; Tolvaptan; Treatment Outcome | 2017 |
Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Blood Pressure; Blood Urea Nitrogen; Creatinine; Female; Heart Failure; Humans; Male; Middle Aged; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan | 2018 |
Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
Topics: Acute Disease; Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Progression; Diuresis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Male; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan; Treatment Outcome | 2017 |
Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Function Tests; Male; Prognosis; Renal Insufficiency, Chronic; Retrospective Studies; Time Factors; Tolvaptan | 2018 |
Tolvaptan Efficiently Reduces Intracellular Fluid: Working Toward a Potential Treatment Option for Cellular Edema.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Diuretics; Edema; Electric Impedance; Female; Humans; Intracellular Fluid; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan | 2019 |
Efficacy of Long-Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Comorbidity; Disease Progression; Female; Heart Failure; Hospitalization; Humans; Japan; Kidney Function Tests; Male; Outcome and Process Assessment, Health Care; Renal Dialysis; Renal Insufficiency, Chronic; Time; Time-to-Treatment; Tolvaptan | 2019 |
Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzhydryl Compounds; Body Composition; Female; Fluid Shifts; Furosemide; Glucosides; Humans; Male; Prospective Studies; Renal Insufficiency, Chronic; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Tolvaptan; Treatment Outcome; Water-Electrolyte Balance; Water-Electrolyte Imbalance | 2019 |
Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Drug Therapy, Combination; Edema; Fluid Shifts; Furosemide; Humans; Leg; Liver Cirrhosis; Male; Renal Insufficiency, Chronic; Tolvaptan | 2019 |
Patient Selection for Tolvaptan Therapy Among Those With Chronic Kidney Disease and Heart Failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Patient Selection; Renal Insufficiency, Chronic; Tolvaptan | 2020 |
Impact of serum albumin levels on the body fluid response to tolvaptan in chronic kidney disease patients.
Topics: Aged; Aged, 80 and over; Body Fluids; Female; Humans; Hypoalbuminemia; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Serum Albumin; Tolvaptan | 2019 |
Successful conversion from thiazide to tolvaptan in a patient with stage d heart failure and chronic kidney disease before heart transplantation.
Topics: Benzazepines; Dose-Response Relationship, Drug; Drug Substitution; Heart Failure; Heart Transplantation; Humans; Hyponatremia; Kidney Function Tests; Male; Middle Aged; Postoperative Complications; Preoperative Care; Renal Agents; Renal Insufficiency, Chronic; Severity of Illness Index; Stroke Volume; Time; Tolvaptan; Treatment Outcome; Trichlormethiazide | 2013 |
The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure.
Topics: Aged; Benzazepines; Creatinine; Diuretics; Heart Failure; Humans; Male; Middle Aged; Osmolar Concentration; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan | 2013 |
Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Topics: Acute Kidney Injury; Adult; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Biomarkers; Cohort Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Glomerular Filtration Rate; Glycopeptides; Humans; Kidney; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Osmolar Concentration; Polycystic Kidney, Autosomal Dominant; Prospective Studies; Renal Insufficiency, Chronic; Severity of Illness Index; Tolvaptan; Treatment Outcome | 2015 |
Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Female; Heart Failure; Humans; Kidney Function Tests; Liver Cirrhosis; Male; Middle Aged; Osmolar Concentration; Renal Insufficiency, Chronic; Retrospective Studies; ROC Curve; Tolvaptan; Urodynamics; Weight Loss | 2015 |
The efficacy of tolvaptan as a diuretic for chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuretics; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Sodium; Tolvaptan; Treatment Outcome; Urination | 2015 |
Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
Topics: Acute Disease; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Creatinine; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Readmission; Renal Insufficiency, Chronic; Retrospective Studies; Tolvaptan | 2016 |
The efficacy of tolvaptan in the perioperative management of chronic kidney disease patients undergoing open-heart surgery.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiac Surgical Procedures; Female; Glomerular Filtration Rate; Heart Diseases; Humans; Male; Perioperative Care; Renal Insufficiency, Chronic; Tolvaptan; Urination | 2017 |
Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Diuresis; Diuretics; Female; Heart Failure; Humans; Kidney; Male; Middle Aged; Osmolar Concentration; Renal Elimination; Renal Insufficiency, Chronic; Retrospective Studies; Sodium; Time Factors; Tolvaptan; Treatment Outcome; Urine; Urodynamics; Weight Loss | 2017 |